Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Quantitative Phase Technology Using Silicon Designed to Visualize Cellular Processes

By BiotechDaily International staff writers
Posted on 16 Oct 2013
A team of scientists has figured out how to quantitatively observe cellular processes taking place on “lab-on-a-chip” devices in a silicon setting.

The new technology should be useful in drug development as well as disease diagnosis, researchers working on the project. In a study published October 2, 2013, in Nature’s online journal Scientific Reports, the investigators reported that it overcame past limitations on quantitative microscopy through an opaque media by working with a new combination of near infrared light and a technique called quantitative phase imaging. The technology is approximately 10-years old and uses shifts in phases of light, not staining techniques, to aid specimen imaging—warranting the term “label-free.”

“To the best of our knowledge, this is the first demonstration of quantitative phase imaging of cellular structure and function in silicon environment,” said Assistant Professor of physics Dr. Samarendra Mohanty, head of the biophysics and physiology laboratory at University of Texas (UT) at Arlington (USA), and corresponding author of the article.

The UT at Arlington and Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) group of scientists was able to study specimens through a silicon wafer in two cases. In one, they achieved full-field imaging of the features of red blood cells to nanometer thickness accuracy. They observed, in another specimen, the dynamic variation of human embryonic kidney cells in response to variations in salt concentration. Dr. Mohanty believes that his group’s current research on near-infrared quantitative-phase imaging can lead to noninvasive, label-free monitoring of neuronal activities.

“Silicon-based microdevices known as labs-on-a-chip are revolutionizing high throughput analysis of cells and molecules for disease diagnosis and screening of drug effects. However, very little progress has been made in the optical characterization of samples in these systems,” said Dr. Bipin Joshi, a recent graduate and lead author of the study. “The technology we’ve developed is well-suited to meet this need.”

Dr. Barman, now an assistant professor at Johns Hopkins University (Baltimore, MD, USA), stated that this study is an excellent example of the type of research he envisages doing, projects driven by needs of the biomedical community and continually pushing the edge of biophotonic technology. “We envision that this significantly expands the visualization possible in silicon based microelectronic and micromechanical devices,” he said.

Related Links:
University of Texas at Arlington
Massachusetts Institute of Technology



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.